Education
About Us
Working with TipRanks
Follow Us
Theratechnologies Inc (TSE:TH)
TSX:TH
TH Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$1.59 - C$3.15
Previous CloseN/A
Volume38.24K
Average Volume (3M)124.33K
Market Cap
$124.15M
Enterprise ValueC$187.24M
Total Cash (Recent Filing)$3.17M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Jul 10, 2025EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding45,980,020
10 Day Avg. Volume249,197
30 Day Avg. Volume124,329
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.85
Price to Cash Flow (P/CF)-80.00
P/FCF Ratio1.70
Enterprise Value/Market Cap1.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.86
Enterprise Value/Ebitda32.86
Forecast
1Y Price Target
C$4.18Price Target Upside54.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Bulls Say, Bears Say
Bulls Say
Acquisition OpportunitiesAcquisition negotiations are ongoing with multiple parties, increasing the likelihood of a favorable outcome for Theratechnologies.
Competitive AdvantagePatent protection for EGRIFTA WR extends into 2033, providing a long-term competitive advantage.
Product DevelopmentThe transition to EGRIFTA WR is expected to drive medium- to long-term growth in the franchise.
Bears Say
Operational UncertaintyNear-term uncertainty exists due to a manufacturing pause on the key revenue-driving asset EGRIFTA SV and uncertainty regarding the expansion of the company's pipeline/portfolio.
Regulatory ChallengesThere will be a delay in the adoption of the new EGRIFTA WR formulation by payors, meaning the full impact is unlikely to be realized soon.
Revenue ChallengesThe shortage resulted in an expected $10M — $12M one-time reduction in revenue, and weaker sales are anticipated in the short term.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.06%
Mutual Funds
23.44% Other Institutional Investors
76.51% Public Companies and
Individual Investors
TH FAQ
What was Theratechnologies Inc’s price range in the past 12 months?
Theratechnologies Inc lowest stock price was C$1.59 and its highest was C$3.15 in the past 12 months.
What is Theratechnologies Inc’s market cap?
Theratechnologies Inc’s market cap is $124.15M.
When is Theratechnologies Inc’s upcoming earnings report date?
Theratechnologies Inc’s upcoming earnings report date is Jul 10, 2025 which is in 86 days.
How were Theratechnologies Inc’s earnings last quarter?
Currently, no data Available
Is Theratechnologies Inc overvalued?
According to Wall Street analysts Theratechnologies Inc’s price is currently Undervalued.
Does Theratechnologies Inc pay dividends?
Theratechnologies Inc does not currently pay dividends.
What is Theratechnologies Inc’s EPS estimate?
Theratechnologies Inc’s EPS estimate is -0.02.
How many shares outstanding does Theratechnologies Inc have?
Theratechnologies Inc has 45,980,020 shares outstanding.
What happened to Theratechnologies Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Theratechnologies Inc?
Currently, no hedge funds are holding shares in TSE:TH
---
Theratechnologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$4.18 (54.78% Upside)
C$4.18 (54.78% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 11.6%
Last 30 Days ▼ 11.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-21.69%
Trailing 12-Months
Company Description
Theratechnologies Inc
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
---
TH Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and new product approval, indicating positive market momentum. However, challenges such as the drug shortage and declining Trogarzo sales were significant concerns. The company's strategic focus on transitioning to the new product formulation and managing operational efficiencies shows resilience.Read More>---
TH Stock 12 Month Forecast
Average Price Target
C$4.18
▲(54.78% Upside)
Technical Analysis
Oncolytics Biotech
―
Bausch Health Companies
―
Neo Performance Materials Inc
―
HLS Therapeutics Inc
―
Premier Health of America Inc
―
Best Analysts Covering TH
1 Year
1 Year Success Rate
8/15 ratings generated profit
1 Year Average Return
+6.57%
reiterated a buy rating 2 months ago
Copying Andre Uddin's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +6.57% per trade.
---